144 related articles for article (PubMed ID: 9058704)
1. Selection for drug resistance results in resistance to Fas-mediated apoptosis.
Landowski TH; Gleason-Guzman MC; Dalton WS
Blood; 1997 Mar; 89(6):1854-61. PubMed ID: 9058704
[TBL] [Abstract][Full Text] [Related]
2. Myeloma cells selected for resistance to CD95-mediated apoptosis are not cross-resistant to cytotoxic drugs: evidence for independent mechanisms of caspase activation.
Landowski TH; Shain KH; Oshiro MM; Buyuksal I; Painter JS; Dalton WS
Blood; 1999 Jul; 94(1):265-74. PubMed ID: 10381522
[TBL] [Abstract][Full Text] [Related]
3. Drug resistance does not correlate with resistance to Fas-mediated apoptosis.
Cullen KV; Davey RA; Davey MW
Leuk Res; 2001 Jan; 25(1):69-75. PubMed ID: 11137563
[TBL] [Abstract][Full Text] [Related]
4. Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells.
Tamiya S; Etoh K; Suzushima H; Takatsuki K; Matsuoka M
Blood; 1998 May; 91(10):3935-42. PubMed ID: 9573032
[TBL] [Abstract][Full Text] [Related]
5. Fas-resistance in ATL cell lines not associated with HTLV-I or FAP-1 production.
Yamada Y; Sugahara K; Tsuruda K; Nohda K; Hata T; Maeda T; Honda M; Tawara M; Hayashibara T; Joh T; Tomonaga M; Miyazaki Y; Kamihira S
Cancer Lett; 1999 Dec; 147(1-2):215-9. PubMed ID: 10660109
[TBL] [Abstract][Full Text] [Related]
6. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions.
Eischen CM; Kottke TJ; Martins LM; Basi GS; Tung JS; Earnshaw WC; Leibson PJ; Kaufmann SH
Blood; 1997 Aug; 90(3):935-43. PubMed ID: 9242521
[TBL] [Abstract][Full Text] [Related]
7. Deficient activation of the CD95 (APO-1/Fas) system in drug-resistant cells.
Friesen C; Fulda S; Debatin KM
Leukemia; 1997 Nov; 11(11):1833-41. PubMed ID: 9369415
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity.
Mizutani Y; Okada Y; Yoshida O; Fukumoto M; Bonavida B
Cancer; 1997 Mar; 79(6):1180-9. PubMed ID: 9070496
[TBL] [Abstract][Full Text] [Related]
9. Expression of Fas and anti-Fas-mediated apoptosis in human hepatocellular carcinoma cell lines.
Yano H; Fukuda K; Haramaki M; Momosaki S; Ogasawara S; Higaki K; Kojiro M
J Hepatol; 1996 Oct; 25(4):454-64. PubMed ID: 8912144
[TBL] [Abstract][Full Text] [Related]
10. Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel.
Symes JC; Kurin M; Fleshner NE; Medin JA
Mol Cancer Ther; 2008 Sep; 7(9):3018-28. PubMed ID: 18790782
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity.
Micheau O; Solary E; Hammann A; Martin F; Dimanche-Boitrel MT
J Natl Cancer Inst; 1997 Jun; 89(11):783-9. PubMed ID: 9182976
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis in a Fas-resistant, T-cell receptor-sensitive human leukaemic T-cell clone.
Delehanty LL; Payne JA; Farrow SN; Brown R; Champion BR
Immunology; 1997 Mar; 90(3):383-7. PubMed ID: 9155645
[TBL] [Abstract][Full Text] [Related]
13. Fas-mediated modulation of Bcr/Abl in chronic myelogenous leukemia results in differential effects on apoptosis.
Selleri C; Maciejewski JP; Pane F; Luciano L; Raiola AM; Mostarda I; Salvatore F; Rotoli B
Blood; 1998 Aug; 92(3):981-9. PubMed ID: 9680367
[TBL] [Abstract][Full Text] [Related]
14. Fas gene mutation in the progression of adult T cell leukemia.
Maeda T; Yamada Y; Moriuchi R; Sugahara K; Tsuruda K; Joh T; Atogami S; Tsukasaki K; Tomonaga M; Kamihira S
J Exp Med; 1999 Apr; 189(7):1063-71. PubMed ID: 10190897
[TBL] [Abstract][Full Text] [Related]
15. Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells.
Fulda S; Strauss G; Meyer E; Debatin KM
Blood; 2000 Jan; 95(1):301-8. PubMed ID: 10607716
[TBL] [Abstract][Full Text] [Related]
16. Mouse islet cell lysis mediated by interleukin-1-induced Fas.
Yamada K; Takane-Gyotoku N; Yuan X; Ichikawa F; Inada C; Nonaka K
Diabetologia; 1996 Nov; 39(11):1306-12. PubMed ID: 8932996
[TBL] [Abstract][Full Text] [Related]
17. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
18. Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein, Fas and of the novel anti-apoptosis factors IAP (inhibitory of apoptosis proteins).
Notarbartolo M; Cervello M; Dusonchet L; Cusimano A; D'Alessandro N
Cancer Lett; 2002 Jun; 180(1):91-101. PubMed ID: 11911975
[TBL] [Abstract][Full Text] [Related]
19. Frequent downregulation of Fas (CD95) expression and function in melanoma.
Bullani RR; Wehrli P; Viard-Leveugle I; Rimoldi D; Cerottini JC; Saurat JH; Tschopp J; French LE
Melanoma Res; 2002 Jun; 12(3):263-70. PubMed ID: 12140383
[TBL] [Abstract][Full Text] [Related]
20. Fas expression and Fas monoclonal antibody-induced apoptosis in a human squamous cell carcinoma cell line, SCC-25.
Seta C; Fujita M; Muraki Y; Fukuda J; Kobayashi S; Haneji T
J Oral Pathol Med; 2000 Jul; 29(6):271-8. PubMed ID: 10890558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
